<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Aspirin (75 to 100 mg) compared with no aspirin in the primary prevention of cardiovascular disease and cancer</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Aspirin (75 to 100 mg) compared with no aspirin in the primary prevention of cardiovascular disease and cancer</h1>
<div class="graphic"><div class="figure"><div class="ttl">Aspirin (75 to 100 mg) compared with no aspirin in the primary prevention of cardiovascular disease and cancer</div><div class="cntnt"><table cellspacing="0"><colgroup span="6" width="16%"></colgroup> <tbody> <tr> <td class="subtitle1" rowspan="2">Outcomes</td> <td class="subtitle1" rowspan="2">Number of participants (studies), follow-up</td> <td class="subtitle1" rowspan="2">Certainty of the evidence (GRADE)</td> <td class="subtitle1" rowspan="2">Relative effect<br/> (95% CI)</td> <td class="subtitle1" colspan="2">Anticipated absolute effects over 10 years</td> </tr> <tr> <td class="subtitle2">Risk with placebo</td> <td class="subtitle2">Risk difference with aspirin*</td> </tr> <tr> <td class="divider_bottom" rowspan="2"> <p><strong>Total mortality</strong></p> Follow-up: range 3.8 to 10 years<sup>[1-4]</sup></td> <td class="divider_bottom" rowspan="2">161,660 (13 RCTs)</td> <td class="divider_bottom" rowspan="2"><span style="font-size: 1.5em;">⊕⊕⊕</span><br/> <strong>MODERATE</strong><br/> due to imprecision<sup>¶</sup></td> <td class="divider_bottom" rowspan="2"><strong>RR 0.97</strong><br/> (0.93 to 1.02)</td> <td colspan="2"><strong>60-year-old person</strong><sup>Δ</sup></td> </tr> <tr> <td class="divider_bottom indent1">83 per 1000<sup>Δ</sup></td> <td class="divider_bottom">2 fewer per 1000<br/> (6 fewer to 2 more)</td> </tr> <tr class="divider_top"> <td class="divider_bottom" rowspan="6"> <p><strong>Myocardial infarction (MI)</strong></p> <p>Nonfatal events</p> Follow-up: range 3.8 to 10 years<sup>[1,2,4]</sup></td> <td class="divider_bottom" rowspan="6">142,566 (12 RCTs)</td> <td class="divider_bottom" rowspan="6"><span style="font-size: 1.5em;">⊕⊕⊕⊕</span><br/> <strong>HIGH</strong></td> <td class="divider_bottom" rowspan="6"><strong>RR 0.83</strong><br/> (0.76 to 0.90)</td> <td colspan="2"><strong>Low cardiovascular risk population</strong><sup>◊</sup></td> </tr> <tr> <td class="indent1">27 per 1000<sup>§</sup></td> <td>5 fewer per 1000<br/> (6 fewer to 3 fewer)</td> </tr> <tr> <td colspan="2"><strong>Moderate cardiovascular risk population</strong><sup>◊</sup></td> </tr> <tr> <td class="indent1">83 per 1000<sup>§</sup></td> <td>14 fewer per 1000<br/> (20 fewer to 8 fewer)</td> </tr> <tr> <td colspan="2"><strong>High cardiovascular risk population</strong><sup>◊</sup></td> </tr> <tr> <td class="divider_bottom indent1">136 per 1000<sup>§</sup></td> <td class="divider_bottom">23 fewer per 1000<br/> (33 fewer to 14 fewer)</td> </tr> <tr class="divider_top"> <td class="divider_bottom" rowspan="6"> <p><strong>Stroke</strong></p> <p>Includes nonfatal ischemic and hemorrhagic strokes</p> Follow-up: range 3.8 to 10 years<sup>[1,2,4]</sup></td> <td class="divider_bottom" rowspan="6">127,433 (12 RCTs)</td> <td class="divider_bottom" rowspan="6"><span style="font-size: 1.5em;">⊕⊕⊕</span><br/> <strong>MODERATE</strong><br/> due to imprecision<sup>¶</sup></td> <td class="divider_bottom" rowspan="6"><strong>RR 0.95</strong><br/> (0.85 to 1.06)</td> <td colspan="2"><strong>Low cardiovascular risk population</strong><sup>◊</sup></td> </tr> <tr> <td class="indent1">23 per 1000<sup>§</sup></td> <td>1 fewer per 1000<br/> (3 fewer to 1 more)</td> </tr> <tr> <td colspan="2"><strong>Moderate cardiovascular risk population</strong><sup>◊</sup></td> </tr> <tr> <td class="indent1">65 per 1000<sup>§</sup></td> <td>3 fewer per 1000<br/> (10 fewer to 4 more)</td> </tr> <tr> <td colspan="2"><strong>High cardiovascular risk population</strong><sup>◊</sup></td> </tr> <tr> <td class="divider_bottom indent1">108 per 1000</td> <td class="divider_bottom">5 fewer per 1000<br/> (16 fewer to 6 more)</td> </tr> <tr class="divider_top"> <td class="divider_bottom" rowspan="6"> <p><strong>Major extracranial bleed</strong><sup>¶¶</sup></p> Follow-up: range 3.8 to 10 years<sup>[1,2,4-6]</sup></td> <td class="divider_bottom" rowspan="6">155,911 (11 RCTs)</td> <td class="divider_bottom" rowspan="6"><span style="font-size: 1.5em;">⊕⊕⊕⊕</span><br/> <strong>HIGH</strong></td> <td class="divider_bottom" rowspan="6"><strong>RR 1.46</strong><br/> (1.32 to 1.62)</td> <td colspan="2"><strong>Low cardiovascular risk population</strong><sup>‡</sup></td> </tr> <tr> <td class="indent1">8 per 1000<sup>§</sup></td> <td>4 more per 1000<br/> (3 more to 5 more)</td> </tr> <tr> <td colspan="2"><strong>Moderate cardiovascular risk population</strong><sup>‡</sup></td> </tr> <tr> <td class="indent1">24 per 1000<sup>§</sup></td> <td>11 more per 1000<br/> (8 more to 15 more)</td> </tr> <tr> <td colspan="2"><strong>High cardiovascular risk population</strong><sup>‡</sup></td> </tr> <tr> <td class="divider_bottom indent1">40 per 1000<sup>§</sup></td> <td class="divider_bottom">18 more per 1000<br/> (13 more to 25 more)</td> </tr> <tr class="divider_top"> <td rowspan="6"> <p><strong>Colorectal cancer</strong> (incidence)</p> Follow-up: median 18.3 years<sup>[7]</sup></td> <td rowspan="6">14,033 (4 RCTs)</td> <td rowspan="6"><span style="font-size: 1.5em;">⊕⊕</span><br/> <strong>LOW</strong><br/> due to imprecision<sup>†</sup> and risk of bias<sup>ΔΔ</sup></td> <td rowspan="6"><strong>HR 0.76</strong><br/> (0.60 to 0.96)</td> <td colspan="2"><strong>Low colorectal cancer risk population: Anticipated absolute effect over 20 years</strong><sup>◊◊</sup></td> </tr> <tr> <td class="indent1">30 per 1000**</td> <td>7 fewer per 1000<br/> (12 fewer to 1 fewer)</td> </tr> <tr> <td colspan="2"><strong>Moderate colorectal cancer risk population</strong></td> </tr> <tr> <td class="indent1">53 per 1000**</td> <td>12 fewer per 1000<br/> (21 fewer to 2 fewer)</td> </tr> <tr> <td colspan="2"><strong>High colorectal cancer risk population</strong></td> </tr> <tr> <td class="indent1">100 per 1000**</td> <td>23 fewer per 1000<br/> (39 fewer to 4 fewer)</td> </tr> </tbody></table></div><div class="graphic_lgnd"><strong>GRADE Working Group grades of evidence:</strong>
<ul class="decimal_heading">
<li><strong>High certainty:</strong> We are very confident that the true effect lies close to that of the estimate of the effect.</li>
<li><strong>Moderate certainty:</strong> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.</li>
<li><strong>Low certainty:</strong> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.</li>
<li><strong>Very low certainty:</strong> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of the effect.</li></ul></div><div class="graphic_footnotes">CI: confidence interval; RR: risk ratio; HR: hazard ratio; NCI: National Cancer Institute.<br/>* <strong>The risk difference in the aspirin group</strong> (and its 95% CI) is based on the estimated risk in the comparison group and the <strong>relative effect</strong> of the intervention (and its 95% CI).<br/>¶ The 95% CI for the absolute effect includes no benefit of aspirin. We did not rate down for risk of bias, but this was a borderline decision. Three of the trials did not blind patients, caregivers, or outcome adjudicator. Sensitivity analyses in meta-analysis by Raju et al<sup>[8]</sup> did not show evidence of risk of bias.<br/>Δ Control group risk estimate for 10-year mortality applies to a 60-year-old person (male or female) and comes from population-based data from Statistics Norway. Mortality increases with age (eg, 50-year-old male; 40 deaths per 1000 in 10 years) and is lower in females than in males (eg, 2.5% in women aged 50 years versus 4% in men aged 50 years).<br/><font class="lozenge">◊</font> Risk groups correspond to low (5%), medium (15%), and high risk (25%) according to the Framingham score (or other risk tool) to estimate 10-year risk.<br/>§ Control group risk estimates in low, moderate, and high cardiovascular risk groups are based on the Framingham score. We have used data from an individual patient data meta-analysis to provide estimated risks for patient-important outcomes not covered by the Framingham risk score. We have also adjusted for 20% overestimation associated with Framingham risk score.<br/>‡ In the individual patient data meta-analysis, risk for future major bleeding correlated with risk for future cardiovascular events. Therefore, we make the assumption that a patient at low, medium, or high risk of future cardiovascular events (determined by Framingham score) will be at low, medium, or high risk of future major bleeding events, respectively.<br/>† The 95% CI for absolute effect borders no benefit of aspirin.<br/>** Moderate control group risk estimate derived from meta-analysis by Rothwell et al.<sup>[7]</sup><br/>¶¶ Major extracranial bleeds are usually from the gastrointestinal tract and are most often defined in those requiring transfusion or resulting in death.<br/>ΔΔ Treatment with aspirin during the included studies ranged from 2.6 to 6.9 years. Colorectal cancer incidence was determined using cancer and death registries for a median of 18.3 years without knowledge of post-treatment period aspirin use.<br/><font class="double_lozenge">◊◊</font> Control group risk estimates based on NCI Colorectal Cancer Risk Predictor Tool.</div><div class="graphic_reference">References:

<ol>
<li>Guirguis-Blake JM, Evans CV, Senger CA, et al. Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the US Preventive Services Task Force: evidence synthesis No 131. AHRQ Publication No. 13-05195-EF-1. Agency for Healthcare Research and Quality, 2015.</li>
<li>ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 2018; 379:1529.</li>
<li>McNeil JJ, Nelson MR, Woods RL, et al. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med 2018; 379:1519.</li>
<li>Gaziano JM, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet 2018; 392:1036.</li>
<li>Ikeda Y, Shimada K, Teramoto T, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA 2014; 312:2510.</li>
<li>McNeil JJ, Wolfe R, Woods RL, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med 2018; 379:1509.</li>
<li>Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010; 376:1741.</li>
<li>Raju N, Sobieraj-Teague M, Hirsh J, et al. Effect of aspirin on cardiovascular and all-cause mortality in primary prevention of cardiovascular disease: a meta-analysis of randomized controlled trials. Am J Med 2011; 124:621.</li>
</ol>

Adapted from: Vandvik PO, Lincoff AM, Gore JM, et al. Primary and Secondary Prevention of Cardiovascular Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e637S.</div><div id="graphicVersion">Graphic 86941 Version 14.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
